Boris Choy, Nonignorable dropout models for longitudinal binary data with random effects: An application of Monte Carlo approximation through the Gibbs output
Mouna Akacha, Implementing Current Regulatory Guidance on the Treatment of Missing Data: An Industry Perspective

Andy Grieve, Dose Selection in Drug Development: What Can Go Wrong? Can we put it Right?
Didier Renard, Use of modeling & simulation to support design and analysis of a new dose and regimen finding study
Björn Bornkamp, On the efficiency of two-stage adaptive designs
H.M. James Hung, Planning and Analyzing Multi-regional Clinical Trials: A Regulatory Perspective
Philip Hougaard, Global drug development strategies
Jørgen Seldrup, Designing clinical trials in a multiregional regulatory environment
Kevin J. Carroll, Consistency of treatment effect across regions in a multi-regional trial: reasonable goal or unrealistic requirement?

Fabrice Bancken, General Principles, Illustrations and Wiki Resources for Improving Statistical Graphs

Further reading:

Ramon Saccilotto, Tutorial for the ggplot2 plotting system for R (based on the book by Hadley Wickham), R code

INTRODUCTION
John Ferguson, Structured Benefit-Risk Optimization (BRO): A Framework Quantitative Decision Support Tools
Gordon Francis, Clinical Perspective on Benefit-Risk Assessments
Lawrence Phillips, Quantitative Benefit-Risk: Determining Values & Assessing Weights
Andrea Beyer, Beyond the Probability of Risk: Measuring Perception, Preferences and Values for Health States

Chrissie Fletcher, Industry Perspective on Comparative Effectiveness Research (CER) and the impact of Health Technology Assessment (HTA) in Europe
Melvin (Skip) Olson, Some Issues with Indirect Comparisons
Friedhelm Leverkus, Health Care Reform in Germany and Update on IQWiG Requirements
John Doyle, Effect of Comparative Effectiveness Research on Drug Development Innovation: a 360° Appraisal and Summary Discussion
Deborah Ashby, Current Methodological Approaches to Benefit-Risk Decision-Making
John Ferguson, Structured Benefit-Risk Optimization (BRO): State-of-the-art and Role of Fully Quantitative Decision Support Tools
Michael Forstner, Considerations for Implementing a Quantitative Benefit-Risk Assessment
Richard Nixon, Benefit-Risk Assessment of Multiple Sclerosis Treatments: Lessons Learnt in the use of Multi-Criteria Decision Analysis
John Doyle, Convergence of CER and BRA and Concluding Summary Discussion

Huque Mohammad, Some key multiplicity questions on primary and secondary endpoints of RCCTs and possible answers
Ferber Georg, Confirmatory statistics in PK/PD studies
Wolf Michael, Control of the false discovery rate under dependence using the bootstrap and sub sampling
Maurer Willi / Glimm Ekkehard, Multiple and repeated testing of primary, co-primary and secondary hypotheses

Kalisch Markus, Can one extract causal information from high-dimensional observational data?
Sauerbrei Willi, Regression model-building with continuous variables – multivariable fractional polynomials, with extensions for interactions

Harald Binder, Fitting and evaluating risk prediction models with high-dimensional molecular data
Martin Wolkewitz, Healthcare epidemiology, hospital-acquired infections, statistical modeling of outbreaks

Your feedback is most welcome.